Logo image of RCEL

AVITA MEDICAL INC (RCEL) Stock Fundamental Analysis

NASDAQ:RCEL - Nasdaq - US05380C1027 - Common Stock - Currency: USD

4.25  -1.13 (-21%)

After market: 4.29 +0.04 (+0.94%)

Fundamental Rating

3

Overall RCEL gets a fundamental rating of 3 out of 10. We evaluated RCEL against 550 industry peers in the Biotechnology industry. RCEL may be in some trouble as it scores bad on both profitability and health. RCEL shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

RCEL had negative earnings in the past year.
RCEL had a negative operating cash flow in the past year.
In the past 5 years RCEL always reported negative net income.
RCEL had a negative operating cash flow in each of the past 5 years.
RCEL Yearly Net Income VS EBIT VS OCF VS FCFRCEL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

RCEL's Return On Assets of -82.01% is on the low side compared to the rest of the industry. RCEL is outperformed by 70.96% of its industry peers.
Industry RankSector Rank
ROA -82.01%
ROE N/A
ROIC N/A
ROA(3y)-45.34%
ROA(5y)-41.63%
ROE(3y)-492.68%
ROE(5y)-311.81%
ROIC(3y)N/A
ROIC(5y)N/A
RCEL Yearly ROA, ROE, ROICRCEL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -200 -400 -600 -800 -1K

1.3 Margins

Looking at the Gross Margin, with a value of 86.47%, RCEL belongs to the top of the industry, outperforming 89.84% of the companies in the same industry.
In the last couple of years the Gross Margin of RCEL has grown nicely.
The Profit Margin and Operating Margin are not available for RCEL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 86.47%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
RCEL Yearly Profit, Operating, Gross MarginsRCEL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -100 -200

More info and screens

2

2. Health

2.1 Basic Checks

RCEL does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, RCEL has about the same amount of shares outstanding.
Compared to 1 year ago, RCEL has a worse debt to assets ratio.
RCEL Yearly Shares OutstandingRCEL Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
RCEL Yearly Total Debt VS Total AssetsRCEL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -7.55, we must say that RCEL is in the distress zone and has some risk of bankruptcy.
RCEL has a worse Altman-Z score (-7.55) than 68.24% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.55
ROIC/WACCN/A
WACC11.08%
RCEL Yearly LT Debt VS Equity VS FCFRCEL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

RCEL has a Current Ratio of 2.09. This indicates that RCEL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.09, RCEL is doing worse than 74.59% of the companies in the same industry.
RCEL has a Quick Ratio of 1.72. This is a normal value and indicates that RCEL is financially healthy and should not expect problems in meeting its short term obligations.
RCEL's Quick ratio of 1.72 is on the low side compared to the rest of the industry. RCEL is outperformed by 78.95% of its industry peers.
Industry RankSector Rank
Current Ratio 2.09
Quick Ratio 1.72
RCEL Yearly Current Assets VS Current LiabilitesRCEL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

7

3. Growth

3.1 Past

RCEL shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.03%.
Looking at the last year, RCEL shows a very strong growth in Revenue. The Revenue has grown by 28.14%.
Measured over the past years, RCEL shows a very strong growth in Revenue. The Revenue has been growing by 30.02% on average per year.
EPS 1Y (TTM)-1.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.67%
Revenue 1Y (TTM)28.14%
Revenue growth 3Y30.02%
Revenue growth 5YN/A
Sales Q2Q%21.22%

3.2 Future

The Earnings Per Share is expected to grow by 35.53% on average over the next years. This is a very strong growth
Based on estimates for the next years, RCEL will show a very strong growth in Revenue. The Revenue will grow by 38.93% on average per year.
EPS Next Y70.82%
EPS Next 2Y38.79%
EPS Next 3Y26.57%
EPS Next 5Y35.53%
Revenue Next Year48.82%
Revenue Next 2Y42.63%
Revenue Next 3Y39.39%
Revenue Next 5Y38.93%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
RCEL Yearly Revenue VS EstimatesRCEL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
RCEL Yearly EPS VS EstimatesRCEL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

RCEL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RCEL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RCEL Price Earnings VS Forward Price EarningsRCEL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RCEL Per share dataRCEL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as RCEL's earnings are expected to grow with 26.57% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.79%
EPS Next 3Y26.57%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RCEL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AVITA MEDICAL INC

NASDAQ:RCEL (8/8/2025, 8:03:08 PM)

After market: 4.29 +0.04 (+0.94%)

4.25

-1.13 (-21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners26.63%
Inst Owner Change-1.99%
Ins Owners0.76%
Ins Owner Change3.02%
Market Cap112.33M
Analysts78.46
Price Target16.45 (287.06%)
Short Float %21.76%
Short Ratio19.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-17.28%
Min EPS beat(2)-34.96%
Max EPS beat(2)0.41%
EPS beat(4)1
Avg EPS beat(4)-21.86%
Min EPS beat(4)-39.31%
Max EPS beat(4)0.41%
EPS beat(8)3
Avg EPS beat(8)-13.87%
EPS beat(12)6
Avg EPS beat(12)-4.64%
EPS beat(16)10
Avg EPS beat(16)3.01%
Revenue beat(2)0
Avg Revenue beat(2)-14.2%
Min Revenue beat(2)-14.25%
Max Revenue beat(2)-14.15%
Revenue beat(4)1
Avg Revenue beat(4)-7.16%
Min Revenue beat(4)-14.25%
Max Revenue beat(4)1.11%
Revenue beat(8)3
Avg Revenue beat(8)-4.03%
Revenue beat(12)7
Avg Revenue beat(12)1.32%
Revenue beat(16)10
Avg Revenue beat(16)3.26%
PT rev (1m)0%
PT rev (3m)-7.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)15.93%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.58%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.76%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.57
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)-1.76
FCFYN/A
OCF(TTM)-1.45
OCFYN/A
SpS2.71
BVpS-0.17
TBVpS-0.38
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -82.01%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 86.47%
FCFM N/A
ROA(3y)-45.34%
ROA(5y)-41.63%
ROE(3y)-492.68%
ROE(5y)-311.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.5%
GM growth 5YN/A
F-Score3
Asset Turnover1.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 570.98%
Cap/Sales 11.51%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.09
Quick Ratio 1.72
Altman-Z -7.55
F-Score3
WACC11.08%
ROIC/WACCN/A
Cap/Depr(3y)370.65%
Cap/Depr(5y)291.06%
Cap/Sales(3y)6.11%
Cap/Sales(5y)5.66%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%36.67%
EPS Next Y70.82%
EPS Next 2Y38.79%
EPS Next 3Y26.57%
EPS Next 5Y35.53%
Revenue 1Y (TTM)28.14%
Revenue growth 3Y30.02%
Revenue growth 5YN/A
Sales Q2Q%21.22%
Revenue Next Year48.82%
Revenue Next 2Y42.63%
Revenue Next 3Y39.39%
Revenue Next 5Y38.93%
EBIT growth 1Y-1.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year59.45%
EBIT Next 3Y27.19%
EBIT Next 5Y22.17%
FCF growth 1Y-139.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-104.28%
OCF growth 3YN/A
OCF growth 5YN/A